TY - JOUR
T1 - Acute Kidney Injury Following Transcatheter Aortic Valve Implantation
T2 - Association with Contrast Media Dosage and Contrast Media Based Risk Predication Models
AU - Sudarsky, Doron
AU - Drutin, Yarden
AU - Kusniec, Fabio
AU - Grosman-Rimon, Liza
AU - Lubovich, Ala
AU - Kinany, Wadia
AU - Hazanov, Evgeni
AU - Gelbstein, Michael
AU - Birati, Edo Y.
AU - Marai, Ibrahim
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/2/23
Y1 - 2022/2/23
N2 - The effect of contrast media (CM), delivered prior to-and during transcatheter aortic valve implantation (TAVI), on kidney function, following the procedure, is debatable. Consequently, the performance of CM-based, acute kidney injury (AKI) risk prediction models is also questionable. We retrospectively studied 210 patients that underwent TAVI. We recorded the dose of CM used prior and during TAVI, calculated the results of different AKI risk assessment models containing a CM module, and tested their association with AKI after the procedure. AKI was diagnosed in 38 patients (18.1%). The baseline estimated glomerular filtration rate (eGFR) was lower in the AKI+ group compared to AKI− group (51 ± 19.3 versus 64.5 ± 19 mL/min/1.73 mr2, respectively). While the dose of CM delivered prior to TAVI, during TAVI or the cumulative amount of both did not differ between the groups, the results of all tested risk models were higher in AKI+ patients. However, by multivariable analysis, only eGFR had a consistent independent association with AKI. We suggest that the dose of CM delivered prior or during TAVI is not associated with AKI and that the predictive power of CM based AKI risk models is, in all probability, limited to eGFR alone.
AB - The effect of contrast media (CM), delivered prior to-and during transcatheter aortic valve implantation (TAVI), on kidney function, following the procedure, is debatable. Consequently, the performance of CM-based, acute kidney injury (AKI) risk prediction models is also questionable. We retrospectively studied 210 patients that underwent TAVI. We recorded the dose of CM used prior and during TAVI, calculated the results of different AKI risk assessment models containing a CM module, and tested their association with AKI after the procedure. AKI was diagnosed in 38 patients (18.1%). The baseline estimated glomerular filtration rate (eGFR) was lower in the AKI+ group compared to AKI− group (51 ± 19.3 versus 64.5 ± 19 mL/min/1.73 mr2, respectively). While the dose of CM delivered prior to TAVI, during TAVI or the cumulative amount of both did not differ between the groups, the results of all tested risk models were higher in AKI+ patients. However, by multivariable analysis, only eGFR had a consistent independent association with AKI. We suggest that the dose of CM delivered prior or during TAVI is not associated with AKI and that the predictive power of CM based AKI risk models is, in all probability, limited to eGFR alone.
KW - Acute kidney injury (AKI)
KW - Contrast media (CM)
KW - Risk models
KW - Transcatheter aortic valve implantation (TAVI)
UR - http://www.scopus.com/inward/record.url?scp=85125152743&partnerID=8YFLogxK
U2 - 10.3390/jcm11051181
DO - 10.3390/jcm11051181
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 35268271
AN - SCOPUS:85125152743
SN - 2077-0383
VL - 11
JO - Journal of Clinical Medicine
JF - Journal of Clinical Medicine
IS - 5
M1 - 1181
ER -